-
Why This Bluebird Bio Analyst Sees Over 125% Upside Ahead
Tuesday, October 20, 2020 - 10:55am | 374Read More...Shares of bluebird bio Inc (NASDAQ: BLUE) are undervalued when weighed against the company's fundamentals, according to a Mizuho Securities analyst. The Bluebird Bio Analyst: Difei Yang initiated coverage of Bluebird bio shares with a Buy rating and $123 price target. The Bluebird Bio...
-
Mizuho Upgrades Audentes On Promising Gene Therapy Candidate
Wednesday, August 8, 2018 - 10:41am | 414Read More...Despite a second-quarter earnings loss, Audentes Therapeutics, Inc. (NASDAQ: BOLD)’s existing catalysts are reason enough for a bullish stance, according to Mizuho. The Analyst Mihuzo analyst Difei Yang upgraded Audentes Therapeutics from Neutral to Buy and raised the price target...
-
FibroGen Upgraded By Mizuho On Continued R&D Progress
Tuesday, May 15, 2018 - 4:29pm | 313Read More...A combination of slightly better-than-expected first-quarter earnings and potential regulatory approval on the horizon have solidified one analysts faith in FibroGen Inc (NASDAQ: FGEN) moving towards the end of the year. The Analyst Mizuho’s Difei Yang upgraded shares of FibroGen from...
-
Concert Pharma Drops On Patent Litigation Setback; Mizuho Downgrades
Friday, January 12, 2018 - 1:48pm | 288Read More...Concert Pharmaceuticals Inc (NASDAQ: CNCE) announced Friday the Patent Trial and Appeal Board decided not to grant the company a Post Grant Review petition in the patent '335 dispute with Incyte Corporation (NASDAQ: INCY). The Analyst Mizuho Securities' Difei Yang decided to downgrade the...
-
ZELTIQ Is The Leader In Non-Invasive Fat Reduction, Says Aegis
Wednesday, December 7, 2016 - 8:39am | 301Read More...Aegis Capital’s Difei Yang believes Zeltiq Aesthetics Inc (NASDAQ: ZLTQ) is well positioned to take “the lion’s share” of the developing body contouring space globally and sees large market opportunity for the company’s “standard setting” product,...
-
Axsome Therapeutics: Teaching Old Drugs New Tricks
Monday, October 3, 2016 - 10:12am | 254Read More...Brean Capital assumed coverage of Axsome Therapeutics Inc (NASDAQ: AXSM) with a Buy rating and $20 target price, implying a potential upside of 154 percent. The company's leading product candidate is AXS-02, a non-opioid therapeutic in development for chronic pain. AXS-02 is being studied...
-
Recro Pharma Offers A Non-Opioid Alternative For Pain Management; Brean Assumes With Buy Rating
Monday, October 3, 2016 - 9:34am | 313Read More...Brean assumed coverage of Recro Pharma Inc (NASDAQ: REPH) with a Buy rating and $21 price target. The firm noted the company focuses on developing non-opioid treatments for the management of acute pain in hospital and ambulatory care settings. The firm sees IV meloxicam as addressing a market,...
-
Brean Assumes SCYNEXIS Shares At Buy, Sees 300% Upside
Monday, October 3, 2016 - 8:46am | 226Read More...Brean Capital assumed coverage of SCYNEXIS Inc (NASDAQ: SCYX) with a Buy rating and target price of $16, implying a potential upside of 313 percent. Scynexis is focusing on the unmet needs surrounding resistant fungal infections. Its lead product candidate, SCY-078, is triterpene glucan...
-
Alder BioPharma Could Lead The Migraine Market; Brean Assumes With Buy Rating
Friday, September 30, 2016 - 8:18am | 433Read More...Alder Biopharmaceuticals Inc (NASDAQ: ALDR) is set to lead in the migraine market, at least according to Brean Capital, which has assumed coverage on the stock with a Buy rating and price target of $45. The company's lead product candidate, ALD403, a novel monoclonal antibody delivered...
-
Brean Likes Nektar Therapeutics' Upcoming Launches; Assumes Coverage At Buy
Friday, September 30, 2016 - 7:34am | 528Read More...Brean Capital assumes coverage of Nektar Therapeutics (NASDAQ: NKTR) with Buy rating and $23 price target on strong growth in royalties from recent and future new launches. "In our view, Nektar's products from recent/future launches that are likely to generate the most upside are: Movantik,...
-
Akebia Price Target Lowered, Still A Buy At Brean
Thursday, September 29, 2016 - 8:05am | 364Read More...Brean Capital assumes coverage of Akebia Therapeutics Inc (NASDAQ: AKBA) with a Buy rating, with a lowered target price of $18, citing potential success of its anemia drug. The company's lead product candidate, AKB-6548 or vadadustat is a small molecule oral drug being studied to treat anemia...
-
Brean Downgrades Pernix Therapeutics, Warns Of Unclear Path To Profitability
Friday, August 12, 2016 - 6:54am | 314Read More...Pernix Therapeutics Holdings Inc (NASDAQ: PTX) reported its 2Q revenue short of expectations. Brean Capitals’ Difei Yang downgraded the rating on the company from Buy to Hold, expressing concern regarding the unclear path to sustainable revenue growth and profitability. Revenue Miss...
-
Galencia's Bid For Relypsa Is 'Reasonable,' Another Bidder 'Unlikely'
Thursday, July 21, 2016 - 9:17am | 382Read More...Swiss healthcare group Galenica has agreed to acquire Relypsa Inc (NASDAQ: RLYP) for $1.53 billion. Relypsa received two downgrades from analysts citing the offer being fair and the low probability of another bidder emerging. Citi Citi’s Yigal Nochomovitz downgraded the rating on the...
-
Evoke Pharma Plunges 70%, Prompting Brean To Downgrade The Stock From Buy
Monday, July 18, 2016 - 10:22am | 330Read More...Evoke Pharma Inc (NASDAQ: EVOK), a specialty pharmaceutical company that focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases, issued a blow to investors Monday morning. Evoke said top-line results from a Phase 3 clinical trial of EVK-001 in female patients...
-
June Data On Relypsa's Veltassa 'Very Encouraging'
Tuesday, July 12, 2016 - 7:03am | 298Read More...Relypsa Inc (NASDAQ: RLYP) announced data on Veltassa for oral suspension at the National Kidney Foundation 2016 Spring Clinical Meetings in Boston. Veltassa June numbers were very encouraging, Brean Capital’s Difei Yang said in a report. He reiterated a Buy rating for the company, with a...
